 |
27 Diseases |  |
0 Trials |
|
0 Trials |  |
30 News |  |
- || Review, Journal: Primary biliary cholangitis: a summary of pathogenesis and therapies. (Pubmed Central) - Mar 24, 2025
agonists, biologics such as dacetuzumab and rituximab, and experimental approaches such as stem-cell therapy, offer promising advances in managing PBC. Liver transplantation remains a final treatment option for advanced cases.
- | dacetuzumab (SGN-40) / Pfizer, bleselumab (ASKP1240) / Astellas, Kyowa Kirin
Journal: Crystal structures of human CD40 in complex with monoclonal antibodies dacetuzumab and bleselumab. (Pubmed Central) - May 5, 2024
Our results offer important insights for future structural and functional studies of CD40 and provide clues to understanding the mechanism of biological response. These data can be applied to developing new strategies for designing antibodies with more therapeutic efficacy.
- Keytruda (pembrolizumab) / Merck (MSD), dacetuzumab (SGN-40) / Seagen, cifurtilimab (SEA-CD40) / Seagen
Updated results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC; SGNS40-001). (Available On Demand; Poster Board No. K15) - Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_566;
P1
This regimen may warrant further evaluation. Clinical trial information: NCT02376699.
- dacetuzumab (SGN-40) / Seagen, SEA-CD40 / Seagen
Phase 2 study of SEA-CD40 combination therapies in advanced malignancies (SGNS40-002, trial in progress) (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1023;
P1, P2
All patients will provide written informed consent. Consent All patients will provide written informed consent.
- | Journal: Immunotherapy in indolent Non-Hodgkin's Lymphoma. (Pubmed Central) - Jun 8, 2022
Other agents include MAB targeting T-Cells like mogamulizumab, Denileukin Diftitox and BiTEs or bispecific T cell engagers like Mosunetuzumab, Glofitamab, and Epcoritamab...Another important aspect in immunotherapy is the half-lives of the medication which is an important factor that can influence the evaluation of the response. The MAB treatment showed important benefit in the treatment of iNHL and it continuously shows how rapidly it can develop to provide optimum care and benefit to patients with iNHL.
- |||| Investigational MoAb in MM #mmsm #USMRC #MedEd #MedTwitter #myeloma Indatuximab (CD138) Lorvotuzumab (CD56) Dacetuzumab (CD40) Milatuzumab (CD74) Tabalumab (BAFF) YS110 (CD26) (Twitter) - Feb 7, 2022
- Keytruda (pembrolizumab) / Merck (MSD), SEA-CD40 / Seagen, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Preliminary results of a phase 1 study of sea-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). (In-Person Only | Level 1, West Hall; Poster Board - G10) - Jan 8, 2022 - Abstract #ASCOGI2022ASCO_GI_818;
P1
Evidence of immune activation was observed, consistent with the proposed mechanism of action. Follow-up for response and survival are ongoing.
- || Campath (alemtuzumab) / Sanofi, Darzalex IV (daratumumab) / J&J
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Updating targets for natural killer/T-cell lymphoma immunotherapy. (Pubmed Central) - Dec 16, 2021
Additionally, dacetuzumab and Campath-1H have demonstrated promising results...Cellular immunotherapy may be used either as maintenance therapy following initial induction chemotherapy or in cases of relapsed/refractory disease. The present review outlines the known immunotherapy targets for the treatment of NKTCL.
- | Revlimid (lenalidomide) / BMS
Retrospective data, Journal: Network meta-analysis of targeted therapies for diffuse large B cell lymphoma. (Pubmed Central) - Apr 29, 2021
This study provides the best treatment strategy for DLBCL patients in terms of overall survival, events-free survival, and overall response rate. The findings of this study require validation with further large-scale RCTs.
- Keytruda (pembrolizumab) / Merck (MSD), SEA-CD40 / Seagen, Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
[VIRTUAL] Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC) (trial in progress). () - Dec 9, 2020 - Abstract #ASCOGI2021ASCO_GI_450;
Assessment of dose-limiting toxicity will occur initially in groups of 6 pts to identify the recommended phase 2 dose of SEA-CD40 for the cohort. Enrollment to this cohort began in November 2019.
- || Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Review, Journal: Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma. (Pubmed Central) - Aug 28, 2020
Newer options are monoclonal anti-CD40 antibody dacetuzumab, anti-PD-1 and anti-PD-L1 checkpoint inhibitors, and Bruton tyrosine kinase inhibitors...In aggressive PCDLCBCL, LT, rituximab with polychemotherapy is recommended. Innovative therapies include intralesional oncolytic virotherapy, systemic monoclonal antibodies, and small molecules.
- [VIRTUAL] Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC). (Poster Board 279) - Feb 27, 2020 - Abstract #ASCO2020ASCO_557;
P1
Enrollment to this cohort began in November 2019. Research Funding: Seattle Genetics, Inc.
- | dexamethasone / generics
Clinical, Review, Journal: Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development. (Pubmed Central) - Sep 25, 2019
Combination therapy using mAbs such as indatuximab, pembrolizumab, lorvotuzumab, siltuximab or dacetuzumab with chemotherapy agents produced better outcomes as compared to monotherapies. Further clinical trials investigating mAbs targeting CD38 used in combination therapy are warranted.
- | Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
Journal: Emerging immune targets for the treatment of multiple myeloma. (Pubmed Central) - May 15, 2019
No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab...A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising.
- | dacetuzumab (SGN-40) / Pfizer
Trial completion: A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Dec 17, 2014
P1, N=50, Completed, Sponsor: Seattle Genetics, Inc.
The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising. No longer recruiting --> Completed
- | dacetuzumab (SGN-40) / Pfizer
Trial completion: Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma (clinicaltrials.gov) - Dec 17, 2014
P1, N=44, Completed, Sponsor: Seattle Genetics, Inc.
No longer recruiting --> Completed Recruiting --> Completed
- | dacetuzumab (SGN-40) / Pfizer
Trial completion, Combination therapy: A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Nov 13, 2011
P1, N=18, Completed, Sponsor: Genentech
Recruiting --> Completed Active, not recruiting --> Completed
- | Rituxan (rituximab) / Roche
Trial completion, Combination therapy: A Study of SGN-40 in Combination With Rituximab in Patients With CD20-Positive, Follicular and Marginal Zone B-Cell Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Nov 13, 2011
P1, N=22, Completed, Sponsor: Genentech
Active, not recruiting --> Completed Active, not recruiting --> Completed